About Nicox
Nicox is a company based in Valbonne (France) founded in 1996.. Nicox has raised $271.01 million across 12 funding rounds from investors including Merck, Pfizer and HBM Healthcare Investments. The company has 5 employees as of December 31, 2024. Nicox has completed 2 acquisitions, including Aciex Therapeutics and Carragelose. Nicox offers products and services including NCX 470. Nicox operates in a competitive market with competitors including Kriya Therapeutics, Annexon, Aldeyra, Gyroscope and MeiraGTx, among others.
- Headquarter Valbonne, France
- Employees 5 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Nicox Sa
-
Annual Revenue
$8.17 M (USD)13.84as on Dec 31, 2024
-
Net Profit
$-23.26 M (USD)-7.23as on Dec 31, 2024
-
EBITDA
$-38.39 M (USD)-81.87as on Dec 31, 2024
-
Total Equity Funding
$271.01 M (USD)
in 12 rounds
-
Latest Funding Round
$10.26 M (USD), Series C
Nov 22, 2022
-
Investors
Merck
& 6 more
-
Employee Count
5
as on Dec 31, 2024
-
Investments & Acquisitions
Aciex Therapeutics
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Nicox
Nicox is a publicly listed company on the EURONEXT with ticker symbol ALCOX in France, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Nicox
Nicox offers a comprehensive portfolio of products and services, including NCX 470. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Lead candidate for glaucoma treatment through nitric oxide mechanisms.
Unlock access to complete
Funding Insights of Nicox
Nicox has successfully raised a total of $271.01M across 12 strategic funding rounds. The most recent funding activity was a Series C round of $10.26 million completed in November 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 12
- Last Round Series C — $10.3M
-
First Round
First Round
(30 Sep 2004)
- Investors Count 7
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2022 | Amount | Series C - Nicox | Valuation |
investors |
|
| Dec, 2021 | Amount | Series C - Nicox | Valuation |
investors |
|
| Dec, 2020 | Amount | Series C - Nicox | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Nicox
Nicox has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include Merck, Pfizer and HBM Healthcare Investments. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Late-stage life sciences investments are managed via VC and PE.
|
Founded Year | Domain | Location | |
|
Life sciences focused VC firm funding companies in the US and Europe
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Nicox
Nicox has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Aciex Therapeutics and Carragelose. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Therapeutics for ophthalmic allergy and inflammation were developed.
|
2007 | ||||
|
Developer of therapeutic solutions for treating respiratory and infectious diseases
|
2007 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Nicox
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Nicox Comparisons
Competitors of Nicox
Nicox operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Kriya Therapeutics, Annexon, Aldeyra, Gyroscope and MeiraGTx, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of therapeutic solutions for the treatment of diabetes
|
|
| domain | founded_year | HQ Location |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
|
| domain | founded_year | HQ Location |
Drug candidates for immune-mediated diseases are developed by Aldeyra.
|
|
| domain | founded_year | HQ Location |
Mobile SDK developed for app engagement and monetization strategies.
|
|
| domain | founded_year | HQ Location |
Gene therapies for ocular and neurodegenerative diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Nicox
Frequently Asked Questions about Nicox
When was Nicox founded?
Nicox was founded in 1996 and raised its 1st funding round 8 years after it was founded.
Where is Nicox located?
Nicox is headquartered in Valbonne, France. It is registered at Valbonne, Provence-alpes-cote D'azur, France.
Who is the current CEO of Nicox?
Andreas Segerros is the current CEO of Nicox.
Is Nicox a funded company?
Nicox is a funded company, having raised a total of $271.01M across 12 funding rounds to date. The company's 1st funding round was a Series C of $18.2M, raised on Sep 30, 2004.
How many employees does Nicox have?
As of Dec 31, 2024, the latest employee count at Nicox is 5.
What is the annual revenue of Nicox?
Annual revenue of Nicox is $8.17M as on Dec 31, 2024.
What does Nicox do?
Developer of nitric oxide (NO) based therapeutics for glaucoma. The company has developed Nitric Oxide (NO) donating compounds that are used to maintain the intraocular pressure (IOP) in the eyes to prevent glaucoma. The companys lead candidates are VYZULTA (licensed), NCX 470 (phase III), and PDE5 inhibitors (research) to treat glaucoma, NCX 4251 (phase II) to treat blepharitisdry eyes, ZERVIATE (licensed) to treat allergic conjunctivitis, and NCX 4280 to treat morning eye congestion.
Who are the top competitors of Nicox?
Nicox's top competitors include Annexon, Alimera Sciences and MeiraGTx.
What products or services does Nicox offer?
Nicox offers NCX 470.
Is Nicox publicly traded?
Yes, Nicox is publicly traded on EURONEXT under the ticker symbol ALCOX.
How many acquisitions has Nicox made?
Nicox has made 2 acquisitions, including Aciex Therapeutics, and Carragelose.
Who are Nicox's investors?
Nicox has 7 investors. Key investors include Merck, Pfizer, HBM Healthcare Investments, Eyevance, and Armistice Capital.
What is Nicox's ticker symbol?
The ticker symbol of Nicox is ALCOX on EURONEXT.